{"id":"W3160261501","doi":"10.1007/s40273-021-01028-3","title":"Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Breast cancer; Quality-adjusted life year; Tamoxifen; Discontinuation; Aromatase inhibitor; Cost effectiveness; Internal medicine; Oncology; Cost-effectiveness analysis; Health economics; Gynecology; Hazard ratio; Cancer; Public health; Confidence interval","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001680151,0.0007052607,0.001104715,0.001547227,0.001080835,0.003055731,0.001316713,0.001708817,0.007384536],"category_scores_gemma":[0.007012307,0.0003515663,0.002306454,0.003163164,0.000835214,0.0007024123,0.0007162819,0.002549886,0.0002229782],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.07316373,"about_ca_system_score_gemma":0.07799778,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9559093,"about_ca_topic_score_gemma":0.9755499,"domain_scores_codex":[0.9980692,0.000503197,0.00009396471,0.0001246213,0.0006702077,0.0005388142],"domain_scores_gemma":[0.9968509,0.0008264655,0.000423117,0.00002971771,0.0009526528,0.0009170619],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.01633743,0.001167582,0.1050071,0.009176415,0.01014661,0.00171342,0.0008167336,0.07246687,0.002280746,0.06337087,0.1862877,0.5312285],"study_design_scores_gemma":[0.009299464,0.004767759,0.5902537,0.01609384,0.02625732,0.0024506,0.005545438,0.05001169,0.00115334,0.02562197,0.2677436,0.0008013034],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.2293781,0.399621,0.001425799,0.2143834,0.001829144,0.0004287176,0.02363674,0.0001119371,0.1291853],"genre_scores_gemma":[0.8585118,0.1151213,0.001854931,0.01339234,0.001172815,0.00007104291,0.004224834,0.00002966795,0.005621125],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.9268363,"threshold_uncertainty_score":0.5308425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02113951258208011,"score_gpt":0.3660010550140271,"score_spread":0.3448615424319469,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}